Justin Walsh
Stock Analyst at JonesTrading
(4.78)
# 579
Out of 4,649 analysts
393
Total ratings
41.7%
Success rate
24.5%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterated: Buy | $18 | $3.20 | +462.50% | 35 | Aug 14, 2026 | |
| ATNM Actinium Pharmaceuticals | Reiterated: Buy | $9 → $3 | $1.04 | +188.46% | 33 | Aug 14, 2026 | |
| LNTH Lantheus Holdings | Reiterated: Hold | n/a | $100.95 | - | 32 | Aug 14, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $74 → $90 | $42.63 | +111.12% | 8 | Aug 13, 2026 | |
| TLSI TriSalus Life Sciences | Reiterated: Buy | $11 | $5.27 | +108.73% | 15 | Aug 10, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $441 | $366.81 | +20.23% | 12 | Aug 7, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | $50 | $47.42 | +5.44% | 20 | Aug 6, 2026 | |
| BLRX BioLineRx | Rated: Hold | n/a | $2.76 | - | 11 | Jul 31, 2026 | |
| XAIR Beyond Air | Rated: Hold | n/a | $6.32 | - | 12 | Jul 31, 2026 | |
| RNXT RenovoRx | Maintained: Buy | $8 | $1.40 | +471.43% | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.26 | - | 8 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $32.14 | +36.90% | 19 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 → $24 | $0.5374 | +4,365.95% | 5 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.80 | +292.86% | 8 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $4.14 | +624.64% | 14 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.94 | +312.37% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $7.59 | +163.50% | 23 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $2.56 | +1,071.88% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.03 | - | 27 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $113.04 | n/a | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.68 | n/a | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.40 | $0.01 | n/a | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $3.09 | n/a | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $4 | $1.48 | n/a | 9 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.80 | n/a | 12 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $20 | $40.03 | n/a | 2 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $0.296 | n/a | 15 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.25 | n/a | 4 | May 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $0.3999 | n/a | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $58.86 | n/a | 2 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $7 | $0.000001 | n/a | 2 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.76 | n/a | 2 | Nov 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.10 | n/a | 3 | Nov 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $19.84 | n/a | 5 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.1734 | n/a | 1 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $1.47 | n/a | 1 | Feb 17, 2021 |
Perspective Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $18
Current: $3.20
Upside: +462.50%
Actinium Pharmaceuticals
Aug 14, 2026
Reiterated: Buy
Price Target: $9 → $3
Current: $1.04
Upside: +188.46%
Lantheus Holdings
Aug 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $100.95
Upside: -
Definium Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $74 → $90
Current: $42.63
Upside: +111.12%
TriSalus Life Sciences
Aug 10, 2026
Reiterated: Buy
Price Target: $11
Current: $5.27
Upside: +108.73%
Praxis Precision Medicines
Aug 7, 2026
Reiterated: Buy
Price Target: $441
Current: $366.81
Upside: +20.23%
Rapport Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $50
Current: $47.42
Upside: +5.44%
BioLineRx
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.76
Upside: -
Beyond Air
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $6.32
Upside: -
RenovoRx
Jul 29, 2026
Maintained: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.26
Upside: -
Jun 26, 2026
Reiterated: Buy
Price Target: $44
Current: $32.14
Upside: +36.90%
May 18, 2026
Reiterated: Buy
Price Target: $60 → $24
Current: $0.5374
Upside: +4,365.95%
May 18, 2026
Reiterated: Buy
Price Target: $11
Current: $2.80
Upside: +292.86%
May 15, 2026
Reiterated: Buy
Price Target: $30
Current: $4.14
Upside: +624.64%
May 13, 2026
Reiterated: Buy
Price Target: $8
Current: $1.94
Upside: +312.37%
May 12, 2026
Reiterated: Buy
Price Target: $20
Current: $7.59
Upside: +163.50%
Mar 25, 2026
Reiterated: Buy
Price Target: $30
Current: $2.56
Upside: +1,071.88%
Jan 5, 2026
Rated: Hold
Price Target: n/a
Current: $23.03
Upside: -
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $113.04
Upside: n/a
Mar 21, 2025
Rated: Hold
Price Target: n/a
Current: $3.68
Upside: n/a
Oct 30, 2024
Reiterated: Buy
Price Target: $0.40
Current: $0.01
Upside: n/a
Aug 8, 2024
Reiterated: Buy
Price Target: $20
Current: $3.09
Upside: n/a
Jun 4, 2024
Reiterated: Buy
Price Target: $8 → $4
Current: $1.48
Upside: n/a
Jun 6, 2022
Reiterated: Buy
Price Target: $10
Current: $1.80
Upside: n/a
May 19, 2022
Maintained: Buy
Price Target: $16 → $20
Current: $40.03
Upside: n/a
May 19, 2022
Reiterated: Buy
Price Target: $18
Current: $0.296
Upside: n/a
May 10, 2022
Reiterated: Buy
Price Target: $10
Current: $2.25
Upside: n/a
May 4, 2022
Maintained: Buy
Price Target: $7 → $6
Current: $0.3999
Upside: n/a
Apr 7, 2022
Maintained: Buy
Price Target: $10
Current: $58.86
Upside: n/a
Jan 11, 2022
Upgraded: Buy
Price Target: $7
Current: $0.000001
Upside: n/a
Nov 26, 2021
Rated: Hold
Price Target: n/a
Current: $4.76
Upside: n/a
Nov 26, 2021
Rated: Hold
Price Target: n/a
Current: $6.10
Upside: n/a
Nov 17, 2021
Reiterated: Buy
Price Target: $30
Current: $19.84
Upside: n/a
Sep 2, 2021
Initiated Coverage: Buy
Price Target: $40
Current: $0.1734
Upside: n/a
Feb 17, 2021
Initiated Coverage: Buy
Price Target: $4
Current: $1.47
Upside: n/a